Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Oral Presentation at the ESMO Congress 2026

Rhea-AI Summary

Perspective Therapeutics (NYSE American: CATX) announced that updated data from its radiopharmaceutical candidate [212Pb]VMT-α-NET have been accepted for an oral presentation at the ESMO Congress 2026, held October 23–27, 2026, in Madrid, Spain.

The rapid oral presentation, led by Thorvardur Halfdanarson of Mayo Clinic Comprehensive Cancer Center, will cover cohort-level safety and efficacy results for Cohorts 1–3 in advanced SSTR2-positive neuroendocrine tumors. The abstract (Number 2396RO) is scheduled for October 23, 2026, from 4:25–4:30 p.m. CEST. Perspective is running a multi-center, open-label, dose-escalation and dose-expansion trial (NCT05636618) in unresectable or metastatic SSTR2-positive tumors and previously shared interim data at ASCO 2026, with additional data submissions planned through 2027.

News Market Reaction – CATX

+1.36%

+1.36% Session close to close

In the Jul 17 session, CATX gained 1.36%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Recent news reactions ranged from a 2.84% gain on ASCO updates to several modest declines, suggestin...

Analysis

Recent news reactions ranged from a 2.84% gain on ASCO updates to several modest declines, suggesting investors scrutinize each data set carefully. With moderate short interest, subsequent detailed VMT-α-NET results and any safety signals will be key to watch.

Key Figures

ESMO Congress dates: October 23–27, 2026 Abstract details release: October 19, 2026 Abstract number: 2396RO +5 more

8 metrics

ESMO Congress dates October 23–27, 2026 European Society of Medical Oncology (ESMO) Congress 2026 in Madrid

Abstract details release October 19, 2026 Date ESMO plans to release regular abstract details

Abstract number 2396RO [212Pb]VMT-α-NET cohort safety and efficacy abstract at ESMO 2026

Session date October 23, 2026 Rapid oral NETs and endocrine tumours session for VMT-α-NET data

Session time 4:15–5:45pm CEST / 10:15–11:45am EDT Rapid oral NETs and endocrine tumours session at ESMO 2026

Presentation time 4:25–4:30pm CEST / 10:25–10:30am EDT Slot for [212Pb]VMT-α-NET rapid oral presentation

Trial identifier NCT05636618 Multi-center, open-label, dose-escalation and dose-expansion VMT-α-NET study

Data cut-off date April 17, 2026 Interim clinical data presented at 2026 ASCO Annual Meeting

Historical Context

5 past events · Latest: Jul 08 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 08	Leadership change	Neutral	-0.9%	Appointment of new Chief Science Officer and transition of company co-founder.
Jun 03	Clinical trial update	Positive	-1.1%	First meningioma patient dosed in new [212Pb]VMT-α-NET cohort of Phase 1/2a study.
May 21	Conference data preview	Positive	+2.8%	Plan to present updated data from all three clinical programs at ASCO 2026.
May 18	Clinical trial update	Positive	-2.3%	First patients dosed in new cohorts of ongoing Phase 1/2a radiopharmaceutical trials.
May 11	1Q26 earnings report	Neutral	-2.8%	Reported 1Q 2026 results with cash runway into late 2027 and higher R&D spend.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Across recent events, CATX often saw modest share-price declines following news, with one notably positive reaction to broader ASCO clinical data in May 2026.

Key Terms

radiopharmaceutical, somatostatin receptor subtype 2, neuroendocrine tumors, theranostic, +1 more

5 terms

radiopharmaceutical medical

"a radiopharmaceutical development company pioneering advanced treatments for cancers"

A radiopharmaceutical is a special type of medicine that contains a small amount of radioactive material, used primarily for medical imaging or treatment. It can be thought of as a tiny, targeted signal that helps doctors see inside the body or deliver therapy directly to affected areas. For investors, understanding radiopharmaceuticals is important because they represent a growing field within healthcare, driven by advancements in diagnostics and personalized treatments.

somatostatin receptor subtype 2 medical

"designed [212Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2)"

Somatostatin receptor subtype 2 is a specific protein found on certain cells in the body that binds to a hormone called somatostatin, which helps regulate processes like hormone release and cell growth. In medical research and drug development, targeting this receptor can lead to new treatments for diseases such as tumors, making it an area of interest for investors looking at biotech innovations. Its significance lies in its potential to enable more precise therapies and improve patient outcomes.

neuroendocrine tumors medical

"in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs)"

Neuroendocrine tumors are a type of abnormal growth that originates from cells responsible for releasing hormones into the bloodstream. These tumors can develop in various parts of the body and sometimes grow slowly or remain hidden for years. Their potential to affect hormone levels and spread makes them important for investors to monitor, especially as advancements in treatment may influence healthcare company performance.

theranostic medical

"This "theranostic" approach enables visualization of the specific tumor"

A theranostic is a single medical approach or agent that combines diagnosis and treatment—using a test or imaging step to find patients likely to benefit, then delivering a targeted therapy tied to that same marker. For investors, theranostics can speed development, lower the chance of failed trials and concentrate sales on the right patients, like a smart key that both locates the correct lock and opens it, potentially improving clinical and commercial success.

open-label medical

"multi-center, open-label, dose-escalation and dose-expansion study"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, July 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [²¹²Pb]VMT-α-NET program have been accepted for presentation as detailed below at the European Society of Medical Oncology (ESMO) Congress 2026 taking place October 23 to 27, 2026 in Madrid, Spain. ESMO plans to release further details for regular abstracts on October 19, 2026.

Presenter	Abstract Title	Presentation Details
Thorvardur Halfdanarson, Mayo Clinic Comprehensive Cancer Center	Cohort level safety and efficacy results for [212Pb]VMT-α-NET in advanced somatostatin receptor subtype 2 (SSTR2+)-expressing neuroendocrine tumors (NETs): Cohorts 1–3	Abstract Number: 2396RO Session Type: Rapid Oral presentation Session Title: Rapid oral: NETs and endocrine tumours Session Date: October 23, 2026 Session Time: 4:15 – 5:45pm CEST / 10:15 – 11:45am EDT Presentation Time: 4:25 – 4:30pm CEST / 10:25 – 10:30am EDT

About [²¹²Pb]VMT-α-NET

Perspective designed [²¹²Pb]VMT-α-NET to target somatostatin receptor subtype 2 (SSTR2), and to deliver the alpha-emitting radioisotope lead-212, or ²¹²Pb, to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation and dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [²¹²Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies (RPT).

Interim clinical data from the study, with a data cut-off date of April 17, 2026, were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026. These data included efficacy results for half of the patients in Cohort 2 and both patients in Cohort 1. Initial efficacy data for the remaining patients in Cohort 2 and patients in Cohorts 3 and 4 are pending. The Company plans to submit additional data for presentation at future medical conferences in 2026 and 2027.

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including VMT-α-NET (neuroendocrine tumors), VMT01 (melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary ²²⁴Ra/²¹²Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential," or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s preclinical and clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s beliefs that its product candidates address certain unmet medical needs; the Company’s expectations regarding regulatory pathways for its product candidates; the Company’s expectations regarding its interactions with regulatory agencies and the expected timing thereof; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and clinical development activities; economic and market conditions may worsen; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com

FAQ

What did Perspective Therapeutics (CATX) announce about VMT- α-NET at ESMO Congress 2026?

Perspective Therapeutics announced updated data for [212Pb]VMT-α-NET were accepted for rapid oral presentation at ESMO Congress 2026. According to Perspective Therapeutics, the presentation will detail cohort-level safety and efficacy results in advanced SSTR2-positive neuroendocrine tumors, covering Cohorts 1–3 of its ongoing clinical study.

When and where will Perspective Therapeutics present VMT-α-NET data at ESMO 2026?

The VMT-α-NET data will be presented on October 23, 2026, at ESMO Congress 2026 in Madrid, Spain. According to Perspective Therapeutics, the rapid oral session runs 4:15–5:45 p.m. CEST, with the specific presentation from 4:25–4:30 p.m. CEST.

What is the focus of the CATX [212Pb]VMT-α-NET abstract 2396RO at ESMO 2026?

The abstract focuses on cohort-level safety and efficacy for [212Pb]VMT-α-NET in advanced SSTR2-positive neuroendocrine tumors. According to Perspective Therapeutics, abstract 2396RO will report results from Cohorts 1–3 in a multi-center, open-label, dose-escalation and dose-expansion study of unresectable or metastatic SSTR2-positive tumors.

What type of clinical study is Perspective Therapeutics running for VMT-α-NET (CATX)?

Perspective Therapeutics is conducting a multi-center, open-label, dose-escalation and dose-expansion study of [212Pb]VMT-α-NET. According to Perspective Therapeutics, the trial (NCT05636618) enrolls patients with unresectable or metastatic SSTR2-positive tumors who have not received prior radiopharmaceutical therapies, assessing safety and efficacy across dose cohorts.

How does [212Pb]VMT-α-NET from Perspective Therapeutics work in SSTR2-positive tumors?

[212Pb]VMT-α-NET is designed to target somatostatin receptor subtype 2 and deliver the alpha-emitter lead-212 (212Pb) to tumors. According to Perspective Therapeutics, this theranostic radiopharmaceutical aims to concentrate powerful radiation in SSTR2-expressing cancer cells while sparing surrounding tissue through receptor-specific targeting.

What prior clinical data for VMT-α-NET (CATX) were presented before ESMO 2026?

Interim clinical data for [212Pb]VMT-α-NET were presented at the ASCO 2026 Annual Meeting. According to Perspective Therapeutics, those data, with an April 17, 2026 cut-off, included efficacy results for half of Cohort 2 patients and both patients in Cohort 1, with additional cohort data still pending.